作为阿尔茨海默氏症疾病有前途的治疗方法的双素受体对抗剂
S M Ragsdale1, J M Radovich2,3, I I Coiduras1
1Department of Psychology; Program in Neuroscience; Florida State University, Tallahassee, FL USA.
Npj biological timing and sleep
|March 11, 2025
概括
这项研究探讨了睡眠,大脑淋巴清除和阿尔茨海默病 (AD) 之间的联系. 它研究双素受体抗剂 (DORAs) 作为改善睡眠和减少AD病理的潜在治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 睡眠医学 睡眠医学
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 睡眠障碍在阿尔茨海默病 (AD) 中很常见.
- 负责大脑中废物清理的淋巴系统在睡眠期间是活跃的.
- 最近的研究质疑睡眠期间淋巴清除的效率,需要进一步研究.
研究的目的:
- 为了检查睡眠,淋巴功能和阿尔茨海默病之间的复杂关系.
- 为了解决最近的发现,这些发现挑战了睡眠期间淋巴清除的作用.
- 探索双素受体对抗剂 (DORAs) 在管理AD相关睡眠问题和增强大脑清除机制方面的治疗潜力.
主要方法:
- 关于睡眠,淋巴系统和阿尔茨海默病的最新文献的综述.
- 分析最近的研究,质疑睡眠期间的淋巴清除.
- 探索双素受体抗剂 (DORA) 机制及其对睡眠和清除的潜在影响.
主要成果:
- 睡眠期间淋巴清除的精确作用和效率需要进一步阐明.
- 双素受体对抗剂 (DORAs) 在缓解与阿尔茨海默病相关的睡眠障碍方面表现有前途.
- DORA可能会增强大脑清除机制,提供一种新的治疗途径.
结论:
- 了解睡眠期间大脑清除的机制,超出传统的淋巴功能,对于阿尔茨海默病的研究至关重要.
- 双素受体抗剂 (DORAs) 是一个有希望的治疗策略,用于解决睡眠障碍,并可能减少阿尔茨海默病的病理生理学.
- 需要进一步的研究来证实DORA,改善睡眠质量和减少阿尔茨海默病生物标志物之间的联系.
相关概念视频
Alzheimer's Disease: Treatment
142
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
142
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
88
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
88
Sedatives and Hypnotics Drugs: Miscellaneous Agents
143
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
143
Antidepressant Drugs: MAOIs and Other Agents
175
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
175
Alzheimer's Disease: Overview
412
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
412
Drug-Receptor Interaction: Agonist
2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K


